Paula Cannon, PhD

Title(s)Distinguished Professor of Molecular Microbiology & Immunology
SchoolKeck School of Medicine of USC
Phone+1 323 442 1510
vCardDownload vCard
    Other Positions
    Title(s)Associate Director of Cross School Programs for the MESH Academy

    Collapse Overview 
    Collapse Overview
    Cannon Lab Website

    Paula Cannon, PhD, is an Associate Professor of Microbiology at the Keck School of Medicine of USC, where she leads a research team that studies viruses, stem cells and gene therapy. She obtained her PhD from the University of Liverpool in the United Kingdom, and received postdoctoral training as an HIV scientist at both Oxford and Harvard universities. Although HIV remains the main focus of her work, she also studies highly pathogenic hemorrhagic fever viruses, including Ebola and Lassa fever viruses. Cannon has a long-standing interest in the development of gene therapy as a clinical approach to treating HIV infection, and her recent work in this area is aimed at disrupting the viral co-receptor, CCR5, using zinc finger nucleases (ZFNs). This approach is being evaluated in human hematopoietic stem cells to address whether such a therapy could result in a "functional cure" for AIDS patients. Cannon’s research is funded by both the National Institutes of Health and the California Institute for Regenerative Medicine.

    Collapse Research 
    Collapse Research Activities and Funding
    Targeted inactivation of HIV in CNS reservoirs
    NIH/NIMH R01MH113457Apr 20, 2017 - Jan 31, 2022
    Role: Principal Investigator
    Next Generation HSC Gene Therapy for HIV Control and Eradication
    NIH/NHLBI U19HL129902Apr 1, 2015 - Mar 31, 2020
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH/NIAID R33AI110149Nov 21, 2013 - Feb 28, 2019
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH/NIAID R21AI110149Nov 21, 2013 - Oct 31, 2015
    Role: Principal Investigator
    Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
    NIH/NIAID R01AI068546Apr 1, 2006 - Mar 31, 2012
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH/NCRR R42RR019834Jun 1, 2004 - Dec 30, 2009
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH/NCRR R41RR019834Jun 1, 2004 - Nov 30, 2005
    Role: Principal Investigator
    NIH/NIAID R21AI055720Sep 1, 2003 - Aug 31, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Llewellyn GN, Seclèn E, Wietgrefe S, Liu S, Chateau M, Pei H, Perkey K, Marsden MD, Hinkley SJ, Paschon DE, Holmes MC, Zack JA, Louie SG, Haase AT, Cannon PM. A humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1+ and TIGIT+ CD4 T cells. J Virol. 2019 Mar 06. PMID: 30842333.
      View in: PubMed
    2. Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton D. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 2019 Jan 16; 8. PMID: 30648968.
      View in: PubMed
    3. Llewellyn GN, Alvarez-Carbonell D, Chateau M, Karn J, Cannon PM. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol. 2018 Apr; 24(2):192-203. PMID: 29256041.
      View in: PubMed
    4. Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, Orthwein A, Juang YC, Zhang W, Noordermeer SM, Seclen E, Wilson MD, Vorobyov A, Munro M, Ernst A, Ng TF, Cho T, Cannon PM, Sidhu SS, Sicheri F, Durocher D. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat Biotechnol. 2018 01; 36(1):95-102. PMID: 29176614.
      View in: PubMed
    5. Rogers GL, Cannon PM. Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases. Hematol Oncol Clin North Am. 2017 10; 31(5):883-895. PMID: 28895854.
      View in: PubMed
    6. Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017 03 01; 8:14447. PMID: 28248314.
      View in: PubMed
    7. Wang CX, Cannon PM. Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS. 2016 12; 30(12):539-544. PMID: 27854119.
      View in: PubMed
    8. DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016; 3:16067. PMID: 27900346.
      View in: PubMed
    9. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 08; 22(8):839-50. PMID: 27400264.
      View in: PubMed
    10. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. PMID: 27410493.
      View in: PubMed
    11. Wang CX, Cannon PM. The clinical applications of genome editing in HIV. Blood. 2016 05 26; 127(21):2546-52. PMID: 27053530; PMCID: PMC4882804 [Available on 05/26/17].
    12. Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164. PMID: 27668293.
      View in: PubMed
    13. Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon PM. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015 Dec; 33(12):1256-1263. PMID: 26551060.
      View in: PubMed
    14. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology. 2015 Aug 07; 12:67. PMID: 26248668; PMCID: PMC4528709.
    15. Rathbun JY, Droniou ME, Damoiseaux R, Haworth KG, Henley JE, Exline CM, Choe H, Cannon PM. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol. 2015 Aug; 89(16):8428-43. PMID: 26041296; PMCID: PMC4524252.
    16. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon PM, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. Genome editing technologies: defining a path to clinic. Mol Ther. 2015 May; 23(5):796-806. PMID: 25943494.
      View in: PubMed
    17. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015 Mar 05; 519(7541):87-91. PMID: 25707797; PMCID: PMC4352131.
    18. Cannon PM, Kohn DB, Kiem HP. HIV eradication--from Berlin to Boston. Nat Biotechnol. 2014 Apr; 32(4):315-6. PMID: 24714473.
      View in: PubMed
    19. Hofer U, Henley JE, Exline CM, Mulhern O, Lopez E, Cannon PM. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. PMID: 24151324; PMCID: PMC3807977.
    20. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon PM, Zaia JA, DiGiusto DL. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther. 2013 Jun; 21(6):1259-69. PMID: 23587921; PMCID: PMC3677314.
    21. Droniou-Bonzom ME, Cannon PM. A systems biology starter kit for arenaviruses. Viruses. 2012 Dec; 4(12):3625-46. PMID: 23342371; PMCID: PMC3528283.
    22. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol. 2012 May; 86(10):5467-80. PMID: 22398279; PMCID: PMC3347301.
    23. Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol. 2011 Dec; 85(24):13457-62. PMID: 21976641; PMCID: PMC3233171.
    24. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology. 2011 Sep 28; 8:78. PMID: 21955466; PMCID: PMC3192746.
    25. Cannon P, June C. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. PMID: 21242897; PMCID: PMC3066441.
    26. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010 Aug; 28(8):839-47. PMID: 20601939; PMCID: PMC3080757.
    27. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology. 2010 Jun 07; 7:51. PMID: 20529266; PMCID: PMC2890665.
    28. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 2010 Jul; 84(14):7243-55. PMID: 20444895; PMCID: PMC2898217.
    29. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology. 2010 Feb 18; 7:13. PMID: 20167081; PMCID: PMC2831821.
    30. Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon PM. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology. 2010 Jan 26; 7:4. PMID: 20102634; PMCID: PMC2831008.
    31. Lucas TM, Lyddon TD, Cannon PM, Johnson MC. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. J Virol. 2010 Mar; 84(6):2666-74. PMID: 20042505; PMCID: PMC2826068.
    32. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM, Kohn DB. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther. 2009 Dec; 20(12):1607-26. PMID: 19689196; PMCID: PMC4094131.
    33. Martin VK, Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Cannon PM. Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins. J Virol. 2010 Jan; 84(2):1176-82. PMID: 19889757; PMCID: PMC2798354.
    34. Flanagan ML, Oldenburg J, Reignier T, Holt N, Hamilton GA, Martin VK, Cannon PM. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J Virol. 2008 Jan; 82(2):938-48. PMID: 18003730; PMCID: PMC2224602.
    35. Reignier T, Oldenburg J, Flanagan ML, Hamilton GA, Martin VK, Cannon PM. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology. 2008 Feb 20; 371(2):439-46. PMID: 17997467; PMCID: PMC2270610.
    36. Weber EL, Cannon PM. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther. 2007 Sep; 18(9):849-60. PMID: 17767401.
      View in: PubMed
    37. Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon PM. Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology. 2007 Jul 20; 364(1):132-9. PMID: 17397892; PMCID: PMC2743526.
    38. Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon PM. Receptor use by pathogenic arenaviruses. Virology. 2006 Sep 15; 353(1):111-20. PMID: 16797051.
      View in: PubMed
    39. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol. 2006 Mar; 80(6):2924-32. PMID: 16501101; PMCID: PMC1395462.
    40. Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol. 2005 Mar; 79(6):3627-38. PMID: 15731257; PMCID: PMC1075700.
    41. Aguilar HC, Anderson WF, Cannon PM. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol. 2003 Jan; 77(2):1281-91. PMID: 12502845; PMCID: PMC140788.
    42. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002 Dec; 32(4):670-5. PMID: 12426566.
      View in: PubMed
    43. Lin AH, Cannon PM. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 2002 Feb 26; 83(1-2):43-56. PMID: 11864740.
      View in: PubMed